Background: We previously reported on the design and synthesis of novel azatyrosinamide derivatives selective for ras-transformed NIH3T3 cells and with improved toxicity over azatyrosine. This study was aimed at investigating the mechanism of action and the antitumour activity of these compounds in ras-transformed cells. Materials and Methods: Nine azatyrosinamides were previously screened for anticancer activity in both wild-type and ras-transformed NIH3T3 cells; the most active compounds were further tested in vitro and in vivo. Results: HPW98-1 and HPW98-2 induced formation of apoptotic bodies in ras-transformed NIH3T3 cells in vitro and inhibited anchorage-independent growth. Excess tyrosine reduced the cytotoxic effect of azatyrosine, but not of HPW98-1 and HPW98-2. HPW98-1 reduced vascular endothelial growth factor-mediated angiogenesis in a Matrigel plug assay and attenuated growth of a ras-transformed NIH3T3 xenograft and a human SW620 xenograft. Conclusion: Our results support the continued study of HPW98-1 for its potential use in the treatment of RAS-related cancers.

Original languageEnglish
Pages (from-to)425-432
Number of pages8
JournalAnticancer Research
Issue number2
Publication statusPublished - Feb 2013


  • Angiogenesis
  • Antitumour agent
  • Azatyrosinamides
  • NIH3T3
  • Ras
  • SW620 human colon xenograft

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Azatyrosinamides: Novel RAS-related anticancer agents'. Together they form a unique fingerprint.

Cite this